Allogene Therapeutics, Inc. (ALLO)
2.035
-0.06
(-2.63%)
USD |
NASDAQ |
Aug 24, 16:00
2.03
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Total Assets (Quarterly) : 550.09M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 550.09M |
| March 31, 2026 | 395.96M |
| December 31, 2025 | 415.90M |
| September 30, 2025 | 439.77M |
| June 30, 2025 | 470.59M |
| March 31, 2025 | 507.98M |
| December 31, 2024 | 548.71M |
| September 30, 2024 | 589.12M |
| June 30, 2024 | 646.88M |
| March 31, 2024 | 586.35M |
| December 31, 2023 | 642.84M |
| September 30, 2023 | 712.33M |
| June 30, 2023 | 770.97M |
| March 31, 2023 | 746.87M |
| December 31, 2022 | 817.08M |
| September 30, 2022 | 887.57M |
| June 30, 2022 | 947.64M |
| March 31, 2022 | 964.63M |
| Date | Value |
|---|---|
| December 31, 2021 | 1.051B |
| September 30, 2021 | 1.079B |
| June 30, 2021 | 1.127B |
| March 31, 2021 | 1.179B |
| December 31, 2020 | 1.228B |
| September 30, 2020 | 1.222B |
| June 30, 2020 | 1.259B |
| March 31, 2020 | 688.52M |
| December 31, 2019 | 717.80M |
| September 30, 2019 | 695.54M |
| June 30, 2019 | 734.00M |
| March 31, 2019 | 749.37M |
| December 31, 2018 | 773.86M |
| September 30, 2018 | 435.24M |
| June 30, 2018 | 148.84M |
| March 31, 2018 | |
| December 31, 2017 | 0.005M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Cartesian Therapeutics, Inc. | 318.63M |
| Beam Therapeutics, Inc. | 1.386B |
| Kyverna Therapeutics, Inc. | 219.82M |
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 113.92M |
| Shareholders Equity (Quarterly) | 436.18M |
| Debt to Equity Ratio | 0.1811 |
| Current Ratio | 10.72 |
| Net Debt Paydown Yield | 0.28% |